Creating a Broad Therapeutic Platform
Clearside Biomedical is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Our proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs.
Our SCS injection platform is an inherently flexible, in-office, non-surgical procedure intended to provide targeted delivery to the site of disease.
Using our suprachoroidal injection technology that can be used in conjunction with proprietary formulations of existing drugs, novel therapies, as well as future therapeurtic innovastions, we believe that we have created a broad therapeutic platform for developing product candidates to treat serious eye diseases.
We are leveraging our SCS injection platform by building an internal research and development pipeline and by creating external collaborations with other companies.
Our extensive patent portfolio provides us with exclusive rights to develop and commercialize pharmacological agents for treatment of eye diseases via suprachoroidal injection. We believe this proprietary method of administration has the potential to become the standard for the delivery of therapies intended to treat retinal and choroidal diseases. Our drug candidates, SCS Microinjector and method of drug administration into the SCS are protected under numerous issued U.S. patents.